Oncology

#Elicio Therapeutics #KRAS #Oncology #Pancreatic cancer #Phase II trial

Elicio refines its Phase III strategy for ELI-002 7P in pancreatic cancer

Elicio Therapeutics has reported that its Phase II AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) did not meet its endpoint of disease-free survival (DFS).   However, the company says landmark analyses during active ELI-002 7P treatment indicated early treatment benefit. Post-hoc… Read More

#Cancer Research #News

Test for KRAS mutation
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Lessons from 50+ patient-derived KRAS-mutant tumour models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#AI #ASCO #Cancer Research UK #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

This week in Drug Discovery (15 June – 19 June) 

News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW.  This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research.  The top stories:     … Read More

#News

#Cancer research #Clinical trial #Drug discovery #Francis Crick Institute #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

DDW Highlights: 16 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

#Podcasts

Bile duct
#ASCO #Incyte #Oncology #Phase III trial

A potentially practice-changing advance in bile duct cancer

Results presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from the Phase III FIGHT-302 trial showed that Incyte’s pemigatinib (Pemazyre), significantly improved progression-free survival in the first-line setting in cholangiocarcinoma (bile duct cancer).  The drug was compared with gemcitabine and cisplatin, a long-standing… Read More

#Cancer Research #Editor's Choice #News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Cancer research #Clinical trial #Drug discovery #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

This week in Drug Discovery (8 – 12 June) 

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW.  This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers.   The top stories:   … Read More

#News

#Cancer Research Horizons #CAR T-cell therapy #Drug discovery #Oncology #UK

On the Horizon – will In Vivo CAR-T fulfil its potential? 

DDW’s Maria Wallace attended Cancer Research Horizons’ On the Horizon breakfast event to learn more about the latest opportunities and challenges in cancer drug discovery and development.  Leading experts from academia, pharma, biotech and investment met in London, UK Thursday 11 June to discuss the potential of in vivo CAR-T therapies to transform the future of… Read More

#News

Multiple myeloma
#HaemaLogiX #Immunotherapy #Myeloma #Oncology

Redefining targeted immunotherapy in multiple myeloma through antigen innovation

Dr Rosanne Dunn, Co-Founder and Chief Scientific Officer at HaemaLogiX, explores how discovery of a new class of tumour‑specific antigens is transforming how we treat plasma cell dyscrasias. For more than two decades, progress in multiple myeloma has been marked by sustained advances in drug development that have not translated… Read More

#Cancer Research #Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Investment #Life sciences #Oncology

Bead BioPharma emerges from stealth with novel drug platform 

Bead BioPharma has emerged from stealth by submitting a patent for a novel cancer drug platform.  The life sciences company, backed by Archangels, submitted the patent in efforts to launch its formal entry into one of the most competitive sectors of global oncology.  Bead BioPharma is focused on antibody-drug conjugates (ADCs), a class of cancer therapies sometimes… Read More

#Business & Investment #News

#Francis Crick Institute #Lung cancer #Oncology #University College London

New research suggests anti-IL-1β drugs could prevent lung cancer

Researchers at the Francis Crick Institute and University College London (UCL) have identified a 14-protein signature in the blood that could identify who would benefit from cancer prevention drugs.  The signature enabled the team, funded by Cancer Research UK and the European Research Council (ERC), to predict… Read More

#Cancer Research #Editor's Choice #News

Cancer tumour
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking sensitivity and resistance to Pan-RAS(ON) inhibition with KRAS

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Webinar: Decoding sensitivity and resistance to Pan-RAS(ON) inhibition

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived Tumour Models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

Webinar date:
Supported by Champions Oncology
#Webinars

#Breast cancer #Genetics / genomics #Oncology #Precision medicine #University College London

Gene test guides more personalised breast cancer treatment

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, a large international clinical trial led by University College London (UCL) has found.  The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) followed more than 4,400 patients… Read More

#Cancer Research #News